A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors

PURPOSE: We conducted a phase I clinical trial to determine the maximum tolerated dose (MTD) of daily or twice daily vorinostat × 3 days when combined with fixed doses of 5-fluorouracil (FU) and leucovorin every 2 weeks. EXPERIMENTAL DESIGN: Vorinostat doses were escalated in a standard 3 × 3 phase...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fakih, Marwan G., Fetterly, Gerald, Egorin, Merrill J., Muindi, Josephia R., Espinoza-Delgado, Igor, Zwiebel, James A., Litwin, Alan, Holleran, Julianne L., Wang, Kangsheng, Diasio, Robert B.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2931804/
https://ncbi.nlm.nih.gov/pubmed/20463088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0547
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares